Immunovant
IMVT
94 hedge funds and large institutions have $157M invested in Immunovant in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 26 closing their positions.
299% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $629K
0.46% more ownership
Funds ownership: 33.98% → 34.45% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
16% less funds holding
Funds holding: 112 → 94 (-18)
21% less capital invested
Capital invested by funds: $197M → $157M (-$40.5M)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$9.63M |
| 2 |
AGM
Alpine Global Management
New York
|
+$2.53M |
| 3 |
BlackRock
New York
|
+$1.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
Top Sellers
IMVT Hedge Fund Activity: Q2 2022 in Review
94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2022, worth a combined $157M — down 21% from $197M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IMVT and 12 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 31 added.
The largest buyer was Deep Track Capital, adding an estimated $9.63M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.87M.
- 94 institutional investors held Immunovant (IMVT) as of Q2 2022, down from 112 in Q1 2022.
- Funds reported $157M of Immunovant stock for Q2 2022, down 21% quarter-over-quarter.
- 12 funds opened new Immunovant positions in Q2 2022 and 26 closed out, a net change of -14 holders.
- The largest Immunovant buyer in Q2 2022 was Deep Track Capital, an estimated $9.63M added.
- The largest Immunovant seller in Q2 2022 was Octagon Capital Advisors, an estimated $3.87M sold.
Based on aggregated 13F filings for Q2 2022.